2022 Fiscal Year Final Research Report

Development of PET imaging method of 89Zr-trastuzumab with PET/MR and dbPET

Research Project

PDF

Project/Area Number	20K07657
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 50020:Tumor diagnostics and therapeutics-related
Research Institution	Kyoto University
Principal Investigator	Nakamoto Yuji 京都大学, 医学研究科, 教授 (20360844)
Co-Investigator(Kenkyū-buntansha)	志水陽一京都大学, 医学研究科, 講師 (90634212) 河井可奈江 (三宅可奈江) 京都大学, 医学研究科, 特定助教 (60812641) 片岡正子京都大学, 医学研究科, 講師 (10611577) 石守崇好公益財団法人田附興風会, 医学研究所保健・健康研究部, 研究主幹 (70742211) 松本純明京都大学, 医学研究科, 特定助教 (80760769)
Project Period (FY)	2020-04-01 – 2023-03-31
Keywords	核医学 / 乳がん / 89Zr
Outline of Final Research Achievements	For the treatment of breast cancer with high expression of HER2 receptor, Anti-HER2 antibody (trastuzumab) is used. However, its therapeutic effect is not always uniform, so non-invasive prediction of the effect is required before trastuzumab administration. In this study, we aimed to establish an imaging method that can noninvasively evaluate the expression status of HER2 receptors in primary tumors and metastases of breast cancer by using an integrated PET/MRI system or a PET system dedicated to breast cancer as imaging equipment and 89Zr-trastuzumab as a PET diagnostic agent. Within the period of this study, we succeeded in producing 89Zr-trastuzumab with sufficient radioactivity and purity for clinical use using an in-house cyclotron system, and optimized the imaging conditions on PET/CT and PET/MRI systems.
Free Research Field	核医学
Academic Significance and Societal Importance of the Research Achievements	本研究では、臨床利用可能な89Zr-トラスツズマブの製造法を確立するとともに、PET/CTのみならず、PET/MRIにおける撮像法の最適化を行った。本知見を基に今後89Zr-トラスツズマブのPET/CT、PET/MRIおよび乳房専用PET装置での臨床PET試験を実施し、乳がんの原発巣・転移巣におけるHER2受容体の発現状態を非侵襲的に評価できる画像診断法を確立できれば、トラスツズマブの投与前に非侵襲的に効果予測が可能となり、無効群における有害事象の低減、医療費抑制につながることが期待される。